Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis

Laboratoire Innotech International661 enrolled

Overview

POLYGYNAX® is a broad spectrum combination of nystatin, neomycin and polymixin B indicated for the local treatment of vaginitis due to sensitive germs and treatment of non specific vaginitis of adults. POLYGYNAX® has been marketed in France since 1969. Nevertheless, despite the well established use of POLYGYNAX®, there is no clinical study supporting the interest of the combination of antifungal and antibiotics agents versus antifungal agent alone. The aim of this project is to demonstrate that POLYGYNAX® is more effective than miconazole in the treatment of women experiencing symptoms of infectious vaginitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

661

Conditions

Vaginitis

Interventions

POLYGYNAX®

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with an abnormal vaginal discharge associated with one (or more) functional vaginal complaints: vaginal burning and/or vaginal pain and/or vaginal irritation clinically evoking an infectious vaginitis: * bacterial vaginitis * non-specific vaginitis (atypical symptoms) * mixed vaginitis (i.e. suprainfected fungal vaginitis) and able to receive an empirical local treatment Exclusion Criteria: 1. Recurrent patient; i.e. a patient who has had at least 4 episodes of infectious vaginitis in the 12 months prior to inclusion 2. Vaginal infection justifying systemic therapy 3. History of atrophic vaginitis or suspected atrophic vaginitis at inclusion 4. Patient presenting with signs of genital herpes or signs of non-infectious vulvar pathology (vulvodynia, psoriasis, eczema, lichen sclerosus, lichen planus, contact dermatitis, candida intertrigo, vulval intraepithelial neoplasia (VIN)) 5. Patient with current Sexually Transmitted Infection (STI) and/or patients with clinical suspicion of STI 6. Disease or concomitant treatment that could cause decreased immunity (i.e. diabetes mellitus, corticosteroids treatments) 7. Systemic anti-infective treatment (antibiotic, antifungal) within two weeks prior to inclusion 8. Patient menstruating or patient with menometrorrhagia due to hormonal imbalance at the time of inclusion 9. Pregnant or lactating women or delivery within last 1 month

Locations (4)

TURKOVA

Prague, Czechia

PERCEVAL

Lyon, France

MARICIC

Belgrade, Serbia

GATOVA

Martin, Slovakia

Outcomes

Primary Outcomes

Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit

* Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation). * Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment. Not considered as "Treatment Failure": * The need to initiate a specific treatment because of a Sexually Transmitted Infection (STI) (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample at Visit 1 / D1. * Patients presenting with only vulvar complaints not considered as related to infectious vaginitis.

Time frame: 15 days after first treatment administration

Secondary Outcomes

Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient in the Diary

This outcome was evaluated using a Visual Analogue Scale (VAS) completed by the patient. The scale measured the level of each vaginal symptom experienced during the day (vaginal discharge, vaginal burning, vaginal pain and vaginal irritation). Scale ranges = 0 to 100 0=none symptom 100=maximum intensity of symptom Time points used in the calculation= D1 to D14

Time frame: during 14 days after first treatment intake

Number of Patients With Change in Vaginal Discharge Assessed by the Investigator

The vaginal discharge is assessed by the investigator by using a score: 0=absent 1. mild: insufficient for speculum collection 2. moderate: sufficient for speculum collection 3. abundant: visible at the introitus even before speculum introduction.

Time frame: 15 days after first treatment administration

Clinical Treatment Efficacy (Success/Failure) Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Study Visit

Success and Failure (same definition as the primary outcome measure)

Time frame: 22 days after first treatment administration

Investigator's Global Satisfaction

The investigator filled the satisfaction questionnaire during the end of treatment visit. Six ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.

Time frame: 15 days after first administration

Patient's Global Satisfaction

The patient filled the satisfaction questionnaire on her patient's diary at home the eve of the End of Treatment Visit. Six ratings are available: Very Bad, Bad, Somewhat Bad, Somewhat Good, Good and Very Good.

Time frame: 15 days after first administration